Paclitaxel

Open studies are marked with a purple background, closed studies have a grey background, studies to be opened have a white background
16023
Phase I study of lonafarnib (SCH66336) in combination with Herceptin plus paclitaxel in HER-2 neu overexpressing breast cancer.
10003
An EORTC-BG-IDBBC/ECSG phase II study evaluating the role of the multi-drug resistance (MDR) reversor, R101933, in patients with taxane refractory metastatic breast cancer.
55963
A randomized phase III study for the treatment of recurrent epithelial ovarian cancer: Chemotherapy alone versus chemotherapy followed by secondary cytoreductive surgery in patients with a treatment-free interval of more than 12 months-trial 55963
55012
A phase III study of Cisplatin plus Topotecan followed by Paclitaxel plus Carboplatin versus Paclitaxel plus Carboplatin as first line chemotherapy in women with newly diagnosed advanced epithelial ovarian cancer.
55051
A multi-national randomized Phase III GCIG Intergroup Study comparing Pegylated Liposomal Doxorubicin and Carboplatin (CaC) versus Paclitaxel and Carboplatin (TC) in patients with epithelial ovarian cancer in late relapse (>6 months).
08012
Pre-operative chemotherapy in resectable NSCLC. Randomised trial of surgical resection with or without pre-operative chemotherapy in patients with operable non small cell lung cancer (NSCLC) of any stage.
55984
A randomized trial of Adryamicin (A) Cisplatin (P) chemotherapy versus Paclitaxel (T) Adriamycin (A) and Cisplatin (P) in patients with metastatic/relapsed or locally advanced inoperable endometrial cancer.
30987
Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and cisplatin/gemcitabine in patients with metastatic or locally advanced urothelial cancer without prior systemic therapy.
30983
Randomized phase II/III study of Taxol-BEP versus BEP in patients with intermediate prognosis germ cell cancer

Back to Protocol section